Fascin Induces Epithelial-Mesenchymal Transition of Cholangiocarcinoma Cells by Regulating Wnt/β-Catenin Signaling.
BACKGROUND Our preliminary study suggested that the expression of Fascin was increased in cholangiocarcinoma, which indicating poor prognosis The present study aimed to explore the roles and mechanisms of Fascin during the progression of cholangiocarcinoma. MATERIAL AND METHODS We evaluated the knockdown effect of endogenous Fascin expression by Short hairpin RNA (shRNA) in QBC939 cells. Cell proliferation was confirmed by MTS assay. Migration and invasion assay was used to examine the cell invasive ability. Tumorigenesis abilities in vivo were analyzed with a xenograft tumor model. Western blot analysis was used to test epithelial-mesenchymal transition (EMT) biomarkers and critical proteins in the Wnt/β-catenin signaling pathway. RESULTS shRNA-mediated gene knockdown of Fascin significantly inhibited cell proliferation, invasion, and EMT, and shRNA-Fascin markedly inhibited the xenograft tumor volume. Silencing of Fascin up-regulated phosphorylation of β-catenin and decreased its nuclear localization. Additionally, knockdown of Fascin led to the upregulation of β-catenin and E-cadherin expression in plasma membrane fraction of QBC939 cells. CONCLUSIONS Our data indicate a key role of Fascin in cell proliferation, migration, and invasion in cholangiocarcinoma. Fascin promotes EMT of cholangiocarcinoma cells, in part through regulating Wnt/β-catenin signaling.
Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China (mainland).
Xianhai
X
Mao
Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China (mainland).
Xiaohui
X
Duan
Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China (mainland).
Bo
B
Jiang
Br J Cancer. 2014 Oct 14;111(8):1552-61
25117814
J Carcinog. 2015 Feb 23;14:1
25788866
BMC Med. 2013 Feb 26;11:52
23442983
PLoS One. 2014 Sep 02;9(9):e106451
25180681
Technol Cancer Res Treat. 2016 Apr;15(2):322-33
25882880
Oncol Lett. 2015 Jul;10(1):121-130
26170987
Gastroenterology. 2013 Dec;145(6):1215-29
24140396
PLoS One. 2015 May 18;10(5):e0125132
25992623
Gastroenterology. 2014 May;146(5):1386-96.e1-17
24462734
Front Oncol. 2014 Dec 16;4:353
25566496
Biochem Biophys Res Commun. 2014 Oct 10;453(1):112-6
25261721
Cancer Res. 2007 Jul 15;67(14):6844-53
17638895
Oncotarget. 2015 May 30;6(15):13822-34
25360865
J Appl Oral Sci. 2015 Mar-Apr;23(2):169-78
26018309
Int J Biol Sci. 2015 May 01;11(6):701-11
25999793
PLoS One. 2015 Jun 25;10 (6):e0130559
26110787
Stem Cells. 2015 Oct;33(10):2913-24
26086949
Asian Pac J Cancer Prev. 2015;16(4):1307-13
25743790
Dtsch Arztebl Int. 2014 Oct 31;111(44):748-54
25412632
Sci Rep. 2015 Apr 29;5:9841
25923013
Int J Clin Exp Med. 2015 Apr 15;8(4):5506-12
26131130
Am J Med Sci. 2013 Oct;346(4):261-8
23221510
Asian Pac J Cancer Prev. 2013;14(12):7221-7
24460279
Clin Transl Med. 2015 Feb 26;4:6
25852822
Clin Transl Med. 2015 Apr 14;4:14
25932287
Eur J Cancer. 2015 Aug;51(12):1638-49
26025765
Lab Invest. 2009 Nov;89(11):1261-74
19721413
Ann Surg Oncol. 2014 Feb;21(2):487-500
24081803
Oncol Rep. 2015 Aug;34(2):850-8
26058854